* Market Opportunity: Breast Cancer > $20B, 20m Mammograms/year in US, 15% result in "call backs"
​* Technology: Non-invasive saliva testing
* Management Team: Life Sciences Veterans. Artemis/Verinata, Amersham/GE Healthcare, Centrillion, Siemens, and Affymetrix/Panomics

---

The LIFEWAVE CardioConnect® congestive heart failure solution provides a non- invasive, direct and absolute measurement of congestive heart failure exacerbation in an integrated connected care framework. It features a sensor, measuring total lung fluids, intravascular and extravascular. Six million people live with heart failure disease in the US, and patient count is expected to double by 2030. Several of us at DDx have known and worked with this entrepreneur for over ten years. He recently pivoted his company focus and is measuring lung fluid to monitor cardiac health. The company has a dialogue to establish pharma partnerships pending the outcome of their pig studies, which were completed in Q3 2019. Beyond the initial token investment, we had negotiated an additional option to purchase more shares through September 2019 from the company at the same valuation, while also purchasing an option from existing shareholders to buy their shares at the same pre-money valuation through the end of 2019.